# BEAT — HeartBeam Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** BEAT  
**Sources:** 19  
**Published:** 2026-10-11  
**Canonical:** https://app.k3vl4r.com/research/deep-research-beat-heartbeam-inc-catalysts-narrative-risks-6999

---

## Overview (point-in-time, as of 2026-10-11)

HeartBeam, Inc. (NASDAQ: BEAT) is a Santa Clara–based medical technology company developing portable 3D ECG and 12-lead synthesis technologies for arrhythmia assessment and remote cardiac monitoring outside clinical settings [[4]](https://www.rttnews.com/3696534/heartbeam-wins-fda-breakthrough-device-designation-for-at-home-heart-attack-assessment-stock-up.aspx), [[21]](https://www.stocktitan.net/overview/BEAT/), [[20]](https://stockanalysis.com/stocks/beat/). As of Oct 9, 2026, the stock traded around $0.48 with a market cap of ~$27.06M, roughly 56.35M shares outstanding, and a 52-week range of $0.36–$4.00 [[12]](https://www.marketbeat.com/stocks/NASDAQ/BEAT/), [[17]](https://finance.yahoo.com/quote/BEAT/), [[14]](https://stockanalysis.com/stocks/beat/forecast/). It is a sub-$1 penny stock with heavy daily volume swings [[12]](https://www.marketbeat.com/stocks/NASDAQ/BEAT/), [[19]](https://stockanalysis.com/stocks/beat/).

## Key Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-beat-heartbeam-inc-catalysts-narrative-risks-6999 (free to sign up)._